Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J's new hep C med Olysio aced Q2. So why are investors worried?

After J&J unveiled street-beating Q2 results yesterday, fueled in part by Olysio's $831 million in sales for the quarter, its stock price actually dropped. Investors figure Olysio's money-minting capabilities won't last, not with competitors racing toward launch themselves.

J&J med tech sales remain relatively flat for second quarter

Second quarter sales for Johnson & Johnson's ($JNJ) medical devices and diagnostics division mirrored those reported in the first quarter, coming in relatively flat at $7.2 billion as sales in its vision and diabetes lines continued to decline due to price competition.

J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales

Johnson & Johnson is always the first Big Pharma to roll out quarterly results. So, investors and analysts watch J&J's numbers for hints about the rest of the industry. But these days, J&J is more of an anomaly than a leading indicator. Why? Its drug sales are growing--big time.

Private equity plus Big Pharma carve-outs equals gold? Well, maybe

Private equity firms are sitting on a record amount of unspent cash--$1.2 trillion by some estimates. At the same time, Big Pharma companies are looking to cast off off-patent drugs and other old products. Could that make a match?

Boston Scientific's Guidant faces more legal pushback in J&J lawsuit

Boston Scientific's Guidant subsidiary faces more legal pushback in its ongoing breach-of-contract lawsuit against Johnson & Johnson, as a federal judge denied the company's request to toss out the case.

J&J hands over $25M milestone for daratumumab progress

Jan van de Winkel The Danish biotech Genmab has won a $25 million milestone from its $1.1 billion collaboration deal with Johnson & Johnson ($JNJ) on the CD38 antibody daratumumab. The...

Patent office nomination for J&J top IP lawyer would send anti-reform message

The potential nomination of Johnson & Johnson chief intellectual property counsel Philip Johnson as director of the U.S. Patent and Trademark Office suggests efforts to reform the patent system are dying, especially changes to rein in so called patent trolls.

J&J cuts 400 medical device jobs, as Covidien hires more than 100

Hiring ahead of and cutting after mergers is always tricky, but organizational change marches on. Post-merger Johnson & Johnson and pre-merger Covidien are both forging ahead, with cuts in J&J's DePuy Synthes and hiring for Covidien.

J&J, Pfizer in tug-of-war over ads for Infants' Advil

Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.

2013's 10 highest-paid Med Tech CEOs

With more M&A, product development and restructuring on the horizon, med tech CEOs have their work cut out for them in the coming year. But for now, here's the breakdown of what they took home in 2013.